Paclitaxel liposomal - Luye Pharma Group

Drug Profile

Paclitaxel liposomal - Luye Pharma Group

Alternative Names: Liposomal paclitaxel - Luye Pharma Group; Lipusu; Paclitaxel Liposome for Injection

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Developer Luye Pharma Group; Nanjing Sike Pharmaceutical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 04 Oct 2016 No recent reports on development identified - Phase-II for Breast cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
  • 26 Aug 2014 Phase-II clinical trials in Breast cancer (Combination therapy, Neoadjuvant therapy) in China (IV)
  • 19 May 2014 Nanjing Luye Sike Pharmaceutical plans a clinical trial in Breast cancer (neoadjuvant combination therapy) in China (NCT02142010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top